| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
|
N Engl J Med
|
2012
|
52.99
|
|
2
|
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
|
J Clin Oncol
|
2010
|
17.13
|
|
3
|
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
|
N Engl J Med
|
2015
|
11.98
|
|
4
|
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
|
J Clin Oncol
|
2014
|
9.86
|
|
5
|
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.
|
Clin Cancer Res
|
2014
|
8.11
|
|
6
|
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
|
J Clin Oncol
|
2015
|
4.68
|
|
7
|
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.
|
Clin Cancer Res
|
2013
|
3.48
|
|
8
|
From genes to drugs: targeted strategies for melanoma.
|
Nat Rev Cancer
|
2012
|
2.46
|
|
9
|
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.
|
J Clin Oncol
|
2015
|
2.30
|
|
10
|
The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry.
|
Cancer Prev Res (Phila)
|
2015
|
2.17
|
|
11
|
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.
|
J Clin Invest
|
2015
|
1.67
|
|
12
|
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
|
Trends Mol Med
|
2014
|
1.59
|
|
13
|
Assays for predicting and monitoring responses to lung cancer immunotherapy.
|
Cancer Biol Med
|
2015
|
1.23
|
|
14
|
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
|
J Hematol Oncol
|
2016
|
1.12
|
|
15
|
Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.
|
Cancer Immunol Res
|
2013
|
1.12
|
|
16
|
New immunotherapies targeting the PD-1 pathway.
|
Trends Pharmacol Sci
|
2015
|
1.02
|
|
17
|
The vitamin E analogue α-TEA stimulates tumor autophagy and enhances antigen cross-presentation.
|
Cancer Res
|
2012
|
1.01
|
|
18
|
Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring.
|
Front Oncol
|
2013
|
0.89
|
|
19
|
Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer.
|
Cancer J
|
2014
|
0.88
|
|
20
|
Targeting the PD-1 pathway: a promising future for the treatment of melanoma.
|
Arch Dermatol Res
|
2014
|
0.87
|
|
21
|
PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence.
|
Onco Targets Ther
|
2014
|
0.85
|
|
22
|
PD-1 blockade in renal cell carcinoma: to equilibrium and beyond.
|
Cancer Immunol Res
|
2014
|
0.85
|
|
23
|
Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma.
|
Hum Vaccin Immunother
|
2015
|
0.83
|
|
24
|
Clinical Development of Immune Checkpoint Inhibitors.
|
Biomed Res Int
|
2015
|
0.82
|
|
25
|
Evolving Concepts: Immunity in Oncology from Targets to Treatments.
|
J Oncol
|
2015
|
0.81
|
|
26
|
PD-1 and PD-L1 antibodies for melanoma.
|
Hum Vaccin Immunother
|
2014
|
0.80
|
|
27
|
Therapeutic challenges in renal cell carcinoma.
|
Am J Clin Exp Urol
|
2015
|
0.80
|
|
28
|
Cellular and molecular immunology of lung cancer: therapeutic implications.
|
Expert Rev Clin Immunol
|
2014
|
0.79
|
|
29
|
Biomarkers as key contributors in treating malignant melanoma metastases.
|
Dermatol Res Pract
|
2011
|
0.79
|
|
30
|
New targeted treatments for non-small-cell lung cancer - role of nivolumab.
|
Biologics
|
2016
|
0.79
|
|
31
|
Challenges and future perspectives of T cell immunotherapy in cancer.
|
Immunol Lett
|
2015
|
0.78
|
|
32
|
Stock market returns and clinical trial results of investigational compounds: an event study analysis of large biopharmaceutical companies.
|
PLoS One
|
2013
|
0.78
|
|
33
|
Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy.
|
J Clin Immunol
|
2011
|
0.78
|
|
34
|
Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma.
|
ESMO Open
|
2016
|
0.77
|
|
35
|
Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.
|
J Transl Med
|
2016
|
0.77
|
|
36
|
Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions.
|
BioDrugs
|
2014
|
0.76
|
|
37
|
New clinical advances in immunotherapy for the treatment of solid tumours.
|
Immunology
|
2015
|
0.76
|
|
38
|
Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?
|
Oncol Rev
|
2016
|
0.76
|
|
39
|
The role of checkpoints in the treatment of GBM.
|
J Neurooncol
|
2015
|
0.75
|